Anterior|Próximo

Inibidores de BET potencializam a ferroptose do melanoma e a imunoterapia através da inibição de AKR1C2

  • role： First author第一作者
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

  • Introduction：Yu Meng, Hui-Yan Sun and Yi He contributed equally to this work
Yu Meng12345,  
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

    Department of Breast Reconstruction, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300202, China

  • Introduction：Yu Meng, Hui-Yan Sun and Yi He contributed equally to this work
Hui-Yan Sun123456,  
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

  • Introduction：Yu Meng, Hui-Yan Sun and Yi He contributed equally to this work
Yi He12345,  
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

Qian Zhou12345,  
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

Yi-Huang Liu12345,  
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

Hui Su12345,  
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

Ming-Zhu Yin12345,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China

  • Email：zengflorachn@hotmail.com
  • Introduction：*zengflorachn@hotmail.com;
Fu-Rong Zeng7*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

  • Email：chenxiangck@126.com
  • Introduction：chenxiangck@126.com;
Xiang Chen12345*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China

    National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China

    Furong Laboratory, Changsha 410008, China

    Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha 410008, China

    National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha 410008, China

  • Email：dengguangtong@outlook.com
  • Introduction：dengguangtong@outlook.com
Guang-Tong Deng12345*

Resumo

Palavras-chave

melanoma;Bromodomain and extra terminal domain (BET) inhibitor;Ferroptosis;Cell death;AKR1C2;Immunotherapy

References

  1. 1..
    He Y, Dong Y, Chen Y, Zhang G, Zhang H, Lei G, et al. Multi-omics characterization and therapeutic liability of ferroptosis in melanoma. Signal Transduct Target Ther. 2022;7(1):268.
  2. 2..
    Deng G, Zeng F, Su J, Zhao S, Hu R, Zhu W, et al. BET inhibitor suppresses melanoma progression via the noncanonical NF-kappaB/SPP1 pathway. Theranostics. 2020;10(25):11428-43.
  3. 3..
    Zhang PZ, Wang DJ, Zhao Y, Ren SC, Gao K, Ye ZQ, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23(9):1055–62.
  4. 4..
    Gagliardi M, Cotella D, Santoro C, Cora D, Barlev NA, Piacentini M, et al. Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis. 2019;10(12):902.
  5. 5..
    Zeng F, Li Y, Meng Y, Sun H, He Y, Yin M, et al. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Exp Mol Med. 2023;55(2):364–76.
  6. 6..
    Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4.

Leia o texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website